Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback